Accustem Sciences Inc · OTC:ACUT
Accustem Sciences — Investor Presentation (December 2022)
19 slides from Accustem Sciences's investor presentation, Dec 1, 2022
Slide 1: Building Better Oncology Tools
eo = =, ee P< ACCUSTec Building Better Oncology Tools AR ACCUSTEM
Slide 2: Disclaimer
DISCLAIMER The Company has filed a registration statement on Form S-1, as amended (Registration No.: 333- ) with the Securities and Exchange Commission for the offering to which this presentation relates. Before you invest, you should read the registration statement and other documents that we have
Slide 3: Company Overview
COMPANY OVERVIEW Our mission at AccuStem is to provide novel diagnostic tools that optimize outcomes and quality of life for all patients along the continuum of oncology care, from cancer screening through treatment and monitoring. Our focus will be the commercialization of proprietary genomic tests
Slide 4: AccuStem Roadmap to Commercialization
ACCUSTEM ROADMAP TO COMMERCIALIZATION Our focus will be the commercialization of a proprietary genomic test for patients with breast cancer representing an estimated market opportunity greater than $1.3B annually TARGET CANCER ANALYTICAL CLINICAL CLINICAL CMS ASSET MARKET VALIDATION VALIDATION UTILI
Slide 5: AccuStem at a Glance
ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ
Slide 6: The Role of "Stemness" in Cancer
THE ROLE OF “STEMNESS” IN CANCER The cancer stem cell hypothesis is a fundamental concept in cancer biology • Essentially, all tumors arise from precursor cells that are similar to stem cells; these cancer stem cells are highly adaptable and have the ability to grow indefinitely • This hypothesis an
Slide 7: Potential Utility of StemPrint Technology
POTENTIAL UTILITY OF STEMPRINT TECHNOLOGY We believe StemPrintER is the only multi- HANNAH GILMORE, MD gene assay able to accurately assess Chief, Division of Anatomic Pathology “stemness” which may lead to enhanced patient-physician discussions and more effective treatment interventions that will i
Slide 8: Breast Cancer and the StemPrintER Test
BREAST CANCER AND THE STEMPRINTER TEST 2M+ new breast cancer diagnoses annually • No genomic tests to inform surgical approach, benefit of radiation StemPrintER is a novel 20-gene test designed to measure the "stemness" of tumors • By evaluating the underlying "stem" biology of tumors, we believe ou
Slide 9: Validation of StemPrintER in Breast Cancer
VALIDATION OF STEMPRINTER IN BREAST CANCER 1 2 N= 574 N= 644 N= 344 N= 432 StemPrintER is highly prognostic for outcomes StemPrintER outperformed the market leader- in early-stage breast cancer OncotypeDx- in the TransATAC cohort 1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022
Slide 10: Clinical Decision Making in Breast Cancer
CLINICAL DECISION MAKING IN BREAST CANCER BIOPSY SURGERY THERAPY Clinical Questions What is the subtype of cancer? Mastectomy vs. lumpectomy? Adjuvant Chemotherapy? Is patient a candidate for NAC? Sentinel node vs. full axillary dissection? Hormone Therapy? How aggressive is the cancer? Radiation Th
Slide 11: Voice of Breast Cancer Key Opinion Leader
VOICE OF BREAST CANCER KEY OPINION LEADER “Beyond clinical factors and patient preference, we do not currently possess tools to PAT WHITWORTH, MD Breast Surgical Oncology determine the most appropriate surgical interventions, especially the need for and extent of lymph node dissection” “Knowing that
Slide 12: Breast Cancer Genomics Industry
BREAST CANCER GENOMICS INDUSTRY AccuStem Exact Sciences Agendia Hologic Myriad Genetics Veracyte Breast Cancer Product StemPrintER OncotypeDX MammaPrint Endopredict Prosigna Index Global Serviceable 798,000 562,000 562,000 562,000 562,000 562,000 Market Reimbursement (CMS) N/A $3873 $3873 $3873 $387
Slide 13: AccuStem at a Glance
ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ
Slide 14: Opportunity in Lung Cancer
OPPORTUNITY IN LUNG CANCER 2M+ new lung cancer diagnoses annually • No genomic tests to inform surgical approach, benefit of radiation StemPrintER may inform treatment planning in patients with early stage lung cancer • By evaluating the underlying "stem" biology of tumors, we believe our test will
Slide 15: Opportunity in Prostate Cancer
OPPORTUNITY IN PROSTATE CANCER 1.4M+ new prostate cancer diagnoses annually • No genomic tests to inform approach to definitive treatment (e.g., surgery, radiation, ablation) StemPrintER may inform treatment planning in patients with localized prostate cancer • By evaluating the underlying "stem" bi
Slide 16: AccuStem at a Glance
ACCUSTEM AT A GLANCE BREAST CANCER PROGRAM STEMNESS PROGRAM EFFICIENT CORPORATE EXECUTION • In-licensed StemPrintER assay from • Planning to build on current • Proven leadership team with nearly Istituto Europeo di Oncologia (IEO) research of stemness across 60 combined years of experience in differ
Slide 17: Our Leadership Team and Approach: A Proven Track Record
OUR LEADERSHIP TEAM AND APPROACH: A PROVEN TRACK RECORD WENDY BLOSSER, CEO JEFF FENSTERER, COO JOE FLANAGAN, CBO ü 23 years of success building organizations ü 20-year track record in long-term ü 15 years of strategic expertise with in Oncology and Women’s Health strategic planning enhanced by broad
Slide 18: Corporate Board
CORPORATE BOARD GABRIELE CERRONE WENDY BLOSSER JOHN BRANCACCIO SEAN MCDONALD WILLY SIMON Executive chairman Director Director Director Director ü Chairman and ü 25 years of success ü Over 35 years ü Experienced ü Career as an executive founder of TIZIANA launching, relaunching financial experience t
Slide 19: Thank You for Your Consideration
THANK YOU FOR YOUR CONSIDERATION Info@Accustem.com | Accustem.com
AccuStem Sciences — Investor Presentation (December 2022) on 6ix